Pfizer Enjoys 76% Share in the Current Pneumonia Vaccine Industry
Pfizer is the major player accounting for 76% of the total market in value and 71% in volume in 2014. Its product potfolio for Pneumonia vaccine consists of Prevnar 13/Prevenar 13 and Prevenar (7-valent), collectively known as the Prevnar family. The family witnessed an increase of 14% in the operational revenue in 2014. In the US, revenues for Prevnar 13 increased 19% in 2014 mainly due to government purchasing patterns and price increases, and increased demand, primarily driven by additional...
View full press release